Ann-Marie Campbell

USPTO Granted Patents = 59 (Patent Applications = 13)

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 15)

Average Co-Inventor Count = 8.5

ph-index = 17

Forward Citations = 688(Granted Patents)

Forward Citations (Not Self Cited) = 328(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

31 out of 125

Forma Therapeutics, Inc.

patents

6 out of 70

Bayer Pharmaceuticals Corporation

patents

5 out of 15

Valo Early Discovery, Inc.

Cara Therapeutics, Inc.

Bayer Intellectual Property Gmbh

patents

9. 1 out of 2,198

Smithkline Beecham Corporation

11. 1 out of 832,761

Other

patents

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Mutant-Isocitrate Dehydrogenase Inhibitors

Ubiquitin-Specific Protease 7 Inhibitors

Quinazolinones

Pyridin-2(1H)-One Quinolinone Derivatives

Pyrrolotriazinones

Thienopyrimidinones

Fused-Bicyclic Aryl Quinolinone Derivatives

Substituted Imidazoheterocycles

Hyper-Proliferative Disorders

Angiogenesis

Aryl Alkyl Acid Derivatives

Biphenyl-4-Yl-Carbonylamino Acid Derivatives

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

2. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2024-06-25),

3. 11795171 - Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors (2023-10-24),

4. 11739071 - Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors (2023-08-29),

5. 11498913 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2022-11-15),

6. 10981915 - Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors (2021-04-20),

7. 10934299 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2021-03-02),

8. 10927130 - Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors (2021-02-23),

9. 10906916 - Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors (2021-02-02),

10. 10889567 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2021-01-12),

11. 10836741 - Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors (2020-11-17),

12. 10807976 - Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors (2020-10-20),

13. 10577329 - Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2020-03-03),

14. 10550099 - Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors (2020-02-04),

15. 10550098 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2020-02-04),

Title: Inventor Ann-Marie Campbell: Pioneering Innovations in Monroe, CT

Introduction: Ann-Marie Campbell is a visionary inventor based in Monroe, CT, known for her groundbreaking contributions to various industries.

Latest Patents: Ann-Marie Campbell holds several patents in the fields of technology, healthcare, and sustainability, showcasing her diverse range of expertise.

Career Highlights: With a career spanning over two decades, Ann-Marie Campbell has worked with renowned research institutions and companies to develop cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout her career, Ann-Marie Campbell has collaborated with top inventors, patent attorneys, and leading companies to bring her ideas to life, fostering a culture of innovation and excellence.

Conclusion: Ann-Marie Campbell's passion for innovation and her relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

This text is generated by artificial intelligence and may not be accurate.